Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas
Open Access
- 19 November 2018
- journal article
- review article
- Published by Elsevier BV in Advances in Radiation Oncology
- Vol. 4 (2), 268-282
- https://doi.org/10.1016/j.adro.2018.11.005
Abstract
No abstract availableFunding Information
- National Institutes of Health (1R01CA191234-01)
This publication has 136 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapyJournal of Neuro-Oncology, 2010
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Gliomas induce and exploit microglial MT1-MMP expression for tumor expansionProceedings of the National Academy of Sciences, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- High TGFβ-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B GeneCancer Cell, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005